Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer

Colorectal Disease

Volumn 14, Issue 10, 2012, Pages

  Carruthers, R ^a   Tho, L M ^a,b,c   Brown, J ^a   Kakumanu, S ^a   Mccartney, E ^a   Mcdonald, A C ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Biomarkers; Chemoradiotherapy; Neutrophil lymphocyte ratio; Rectal cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD EXAMINATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; HEMATOLOGICAL PARAMETERS; HISTOPATHOLOGY; HUMAN; LOCALLY ADVANCED RECTUM ADENOCARCINOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; PREDICTOR VARIABLE; PREOPERATIVE CHEMORADIATION; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RECTUM CARCINOMA; RETROSPECTIVE STUDY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE COUNT; TIME TO LOCAL RECURRENCE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD CELL COUNT; CHEMORADIOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECTAL NEOPLASMS; RECTUM; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 84866361679     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2012.03147.x     Document Type: Article

References (40)

1. Quirke P. Training and quality assurance for rectal cancer: 20years of data is enough. Lancet Oncol 2003; 4: 695-702.
2. Beets-Tan RG, Beets GL, Vliegen RF et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 2001; 357: 497-504.
3. Brown G. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 2006; 333: 779.
4. Glimelius B, Pahlman L, Cervantes A. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v82-6.
5. Bosset JF, Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-23.
6. Braendengen M, Tveit KM, Berglund A et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008; 26: 3687-94.
7. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-40.
8. Mawdsley S, Glynne-Jones R, Grainger J et al. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival? Int J Radiat Oncol Biol Phys 2005; 63: 745-52.
9. Beresford M, Glynne-Jones R, Richman P et al. The reliability of lymph-node staging in rectal cancer after preoperative chemoradiotherapy. Clin Oncol (R Coll Radiol) 2005; 17: 448-55.
10. Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009; 74: 673-88.
11. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009; 12: 223-6.
12. Proctor MJ, Morrison DS, Talwar D et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011; 47: 2633-41.
13. Roxburgh CS, Salmond JM, Horgan PG et al. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg 2009; 249: 788-93.
14. McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 2007; 22: 881-6.
15. Roxburgh C, McDonald A, Salmond J et al. Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors. Int J Colorectal Dis 2011; 26: 483-92.
16. Ishizuka M, Nagata H, Takagi K, Kubota K. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer. Ann Surg 2009; 250: 268-72.
17. Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg 2007; 246: 1047-51.
18. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91: 181-4.
19. Malik HZ, Prasad KR, Halazun KJ et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg 2007; 246: 806-14.
20. Ding PR, An X, Zhang RX et al. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 2010; 25: 1427-33.
21. Neal CP, Mann CD, Sutton CD et al. Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases. Eur J Cancer 2009; 45: 56-64.
22. Liu H, Liu G, Bao Q et al. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in rectal carcinoma. J Gastrointest Cancer 2010; 41: 116-20.
23. Kitayama J, Yasuda K, Kawai K, Sunami E, Nagawa H. Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. Radiat Oncol 2010; 5: 47.
24. Qiu MZ, Yuan ZY, Luo HY et al. Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumour Biol 2010; 31: 255-60.
25. Tho LM, Glegg M, Paterson J et al. Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning. Int J Radiat Oncol Biol Phys 2006; 66: 505-13.
26. Aliustaoglu M, Bilici A, Ustaalioglu BB et al. The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol 2010; 27: 1060-5.
27. Maughan NJ, Morris E, Forman D, Quirke P. The validity of the Royal College of Pathologists' colorectal cancer minimum dataset within a population. Br J Cancer 2007; 97: 1393-8.
28. Birbeck KF, Macklin CP, Tiffin NJ et al. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg 2002; 235: 449-57.
29. Das P, Skibber JM, Rodriguez-Bigas MA et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 2007; 109: 1750-5.
30. Kwon HC, Kim SH, Oh SY et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012; 17: 216-22.
31. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011; 104: 1288-95.
32. Hung HY, Chen JS, Yeh CY et al. Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis 2011; 26: 1059-65.
33. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 2011; 71: 2411-6.
34. Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010; 138: 2101-14e5.
35. Lin EY, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer 2004; 90: 2053-8.
36. Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 2007; 7: 4.
37. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-4.
38. Mlecnik B, Tosolini M, Kirilovsky A et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29: 610-8.
39. Low G, Tho LM, Leen E et al. The role of imaging in the pre-operative staging and post-operative follow-up of rectal cancer. Surgeon 2008; 6: 222-31.
40. Bujko K, Glynne-Jones R, Bujko M. Adjuvant chemotherapy for rectal cancer. Ann Oncol 2010; 21: 2443.